Skip to main content

InflaRx N.V. (IFRX)

NASDAQ: IFRX · IEX Real-Time Price · USD
2.66 -0.10 (-3.62%)
Oct 21, 2021 1:35 PM EDT - Market open
Market Cap121.51M
Revenue (ttm)n/a
Net Income (ttm)-36.62M
Shares Out44.19M
EPS (ttm)-1.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume610,015
Open2.76
Previous Close2.76
Day's Range2.57 - 2.79
52-Week Range2.23 - 6.88
Beta0.44
AnalystsHold
Price Target9.45 (+255.1%)
Est. Earnings DateOct 28, 2021

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammat...

IndustryBiotechnology
IPO DateNov 8, 2017
Employees47
Stock ExchangeNASDAQ
Ticker SymbolIFRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for InflaRx N.V. stock is "Hold." The 12-month stock price forecast is 9.45, which is an increase of 255.12% from the latest price.

Price Target
$9.45
(255.12% upside)
Analyst Consensus: Hold

News

InflaRx Secures €44M Grant From German Govt To Advance Its COVID-19 Trial

The German Ministry of Education & Research and the Ministry of Health have granted €43.7 million to InflaRx N.V. (NASDAQ: IFRX) to support the development of vilobelimab for COVID-19 patients.

1 day ago - Benzinga

InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of V...

JENA, Germany, Oct. 19, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ann...

2 days ago - GlobeNewsWire

InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ann...

1 week ago - GlobeNewsWire

InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc...

1 month ago - GlobeNewsWire

InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

JENA, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, an...

1 month ago - GlobeNewsWire

InflaRx's Vilobelimab Shows Encouraging Signs Of Drug Activity In Mid-Stage Study With Dermatological Ulcer Patients

InflaRx N.V. (NASDAQ: IFRX) has announced data from the first 10 evaluable patients in the ongoing Phase 2a open-label study with vilobelimab in Pyoderma Gangraenosum (PG).

2 months ago - Benzinga

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab i...

JENA, Germany, Aug. 10, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ann...

2 months ago - GlobeNewsWire

InflaRx to Present at the BTIG Virtual Biotechnology Conference

JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will pre...

2 months ago - GlobeNewsWire

InflaRx Reports Second Quarter 2021 Financial & Operating Results

JENA, Germany, Aug. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announce...

2 months ago - GlobeNewsWire

InflaRx to Present at the Raymond James Human Health Innovation Conference

JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, wil...

4 months ago - GlobeNewsWire

A Trio of Net Current Asset Value Stock Picks

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the s...

Other symbols:ADVMCLBS
4 months ago - GuruFocus

InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...

4 months ago - GlobeNewsWire

Tony Gibney Joins InflaRx Board of Directors

JENA, Germany, May 21, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, toda...

5 months ago - GlobeNewsWire

InflaRx Reports First Quarter 2021 Financial & Operating Results

JENA, Germany, May 12, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced...

5 months ago - GlobeNewsWire

InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis Study

InflaRx NV (NASDAQ: IFRX) has announced topline results from its U.S. Phase 2 IXPLORE study evaluating vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis...

5 months ago - Benzinga

InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE ...

JENA, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced...

5 months ago - GlobeNewsWire

InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum

JENA, Germany, April 15, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, an...

6 months ago - GlobeNewsWire

7 Penny Stocks That May Have Room to Run Higher

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other symbols:AGRXAQMSCKPTHEPALLNW
6 months ago - InvestorPlace

InflaRx Reports Full Year 2020 Financial & Operating Results

JENA, Germany, March 25, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc...

6 months ago - GlobeNewsWire

InflaRx to Present at Upcoming Investor Conferences

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two ...

7 months ago - GlobeNewsWire

InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants

JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, an...

7 months ago - GlobeNewsWire

InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants

JENA, Germany, Feb. 25, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ann...

7 months ago - GlobeNewsWire

InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants

JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ann...

7 months ago - GlobeNewsWire

InflaRx's Vilobelimab Suppresses Inflammation In Mid-Stage Chronic Skin Disorder Study

InflaRx NV (NASDAQ: IFRX) has announced new data Phase 2b SHINE study, evaluating vilobelimab (IFX-1) in moderate and severe Hurley Stage II and III hidradenitis suppurativa (HS), a chronic skin conditi...

8 months ago - Benzinga

InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual...

JENA, Germany, Feb. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today an...

8 months ago - GlobeNewsWire